UK-356618, >=98% (HPLC)

UK-356618, >=98% (HPLC)

Application

UK-356618 has been used as a specific matrix metalloproteinase 3 (MMP3) inhibitor to study its effect on amitriptyline-induced glial cell line-derived neurotrophic factor (GDNF) mRNA expression and to confirm its influence on amitriptyline-induced zymographic MMP-9 activation in rat C6 astroglial cells.

Biochem/physiol Actions

UK-356,618 is a potent, selective inhibitor of Matrix metalloproteinase MMP3 (stromelysin-1). MMP-3 IC50 = 5.9 nM, selectivity is 140-fold vs MMP-1, -2, -9, and -14.

UK 356618 has the potential to inhibit interleukin (IL)-6-induced cell migration in NCI H446 small cell lung cancer cellsin vitro.

Legal Information

Pfizer is a registered trademark of Pfizer, Inc.

Sold for research purposes under agreement from Pfizer Inc.

Other Notes

This compound was developed by Pfizer for Cytoskeleton & Extracellular Matrix research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer.To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Packaging

5, 25 mg in glass bottle

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Colour InChI key InChI Manufacturer Form Assay Price Quantity
3573571 UK-356618, >=98% (HPLC) white to tan JJHRUUKMPWUYIB-HVOSOHGQSA-N 1S/C34H43N3O4/c1-23-21-25(19-20-29(23)27-16-10-7-11-17-27)13-12-18-28(22-30(38)37-41)32(39)36-31(34(3,4)5)33(40)35-24(2)26-14-8-6-9-15-26/h6-11,14-17,19-21,24, SIGMA-ALDRICH powder ≥98% (HPLC)
£498.64 (exc VAT) per 25MG
-
+
3573572 UK-356618, >=98% (HPLC) white to tan JJHRUUKMPWUYIB-HVOSOHGQSA-N 1S/C34H43N3O4/c1-23-21-25(19-20-29(23)27-16-10-7-11-17-27)13-12-18-28(22-30(38)37-41)32(39)36-31(34(3,4)5)33(40)35-24(2)26-14-8-6-9-15-26/h6-11,14-17,19-21,24, SIGMA-ALDRICH powder ≥98% (HPLC)
£179.68 (exc VAT) per 5MG
-
+